Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD.
The decision was made because the company could not obtain favorable results from the current phase II clinical study named the ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) study conducted in the US.
Detailed results of the ACTIVATE study will be presented at the 2005 American Heart Association's Scientific Sessions to be held in Texas on November 15.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Oct 31, 2005|
|Previous Article:||Kagome to Introduce New Collagen Yogurt Drink.|
|Next Article:||Novartis Pharma to Spin off Its Nutrition Business in January.|